Experiments in model systems have shown that FGFR-specific inhibitors may be valuable in treating multiple myeloma, bladder and endometrial cancers. FGF1, FGF2 and FGF4 have been studied in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback